Qiang Zhang et al. [33] found that after 6 months of treatment with nusinersen, Eotaxin and MIP-1β levels in the CSF were significantly decreased, while IL-2, IL-4, and VEGF-A levels were increased in SMA patients. The gene discussed is IL2; the disease is proximal spinal muscular atrophy.